Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.


Expert Opinion / Cases · April 14, 2022

Metastatic CRPC With TP53 and PTEN Mutations

Written by
Pedro C. Barata MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Ismail Abdelhafeez

    Apr 14, 2022

    Neuroendocrine : NCCN : cisplatine + etoposide

  • Waleed Ragab

    Apr 14, 2022

    We may use immunotherapy Pembrolizumab

  • Charles Maack

    Apr 14, 2022

    #4 - cisplatin plus etoposide, though close attention since etoposide can be toxic to liver

  • Zafeiris Zafeiriou

    Apr 15, 2022


  • Paul Kahn

    Apr 15, 2022

    Cis platinum and etoposide

  • Silverio Ros Martínez

    Apr 15, 2022

    Carboplatino + cabazitaxel. It's an agreessive variant anda there os a phase 2 trial with this Combination

  • Comment deleted by Moderator.
  • Martín Oré

    Apr 18, 2022


  • Kristiina Ojamaa

    Apr 28, 2022

    Cabazitaxel and carboplatin. Neuroendocrine features doesn't mean neuroendocrine carcinoma

  • Franz Stoiber

    Apr 30, 2022


  • rodolfo mattioli

    Jun 24, 2022

    cis + vp16

  • Nov 30, 2023

    Pending Moderator approval.

Further Reading